VA-CTA
3.10.2018 22:02:11 CEST | Business Wire | Press release
The Consumer Technology Association (CTA)TM hosted the sixth annual CES Unveiled Paris today, making several announcements and shining a spotlight on the latest tech innovation. Co-located for the first time with the Mondial Paris Motor Show , CES Unveiled Paris gathered innovative exhibitors, media and industry professionals to experience the latest tech trends and products expected at CES® 2019 that will change our world for the better. Owned and produced by CTA, CES 2019 will run January 8-11, 2019 in Las Vegas, Nevada.
During the event, CTA Executive Vice President of CES Karen Chupka announced 55 French companies selected as CES® 2019 Innovation Honorees . Selected Honorees included GEOFLEX in the vehicle intelligence and self-driving category and Pixminds honored in the gaming category.
“CES Unveiled Paris highlights the innovative spirit fueling Europe’s dynamic tech market, and the French companies recognized as this year’s CES Innovation Award honorees represent the future of technology,” said Chupka. “The products and services honored today reflect the ingenuity driving our industry forward and improving the way we live, work and play.”
The remaining Innovation honorees will be announced at CES Unveiled New York on November 8, 2018. The full list of Honorees will be posted online at CES.tech and showcased at CES 2019, January 8-11.
CTA President and CEO Gary Shapiro also announced today that Dr. Lisa Su, president and CEO of AMD, will deliver a keynote at CES 2019. Dr. Su joins IBM CEO Ginni Rometty as confirmed CES 2019 keynote speakers, with additional speakers to be announced in the coming weeks.
Showcasing the latest technology products and celebrating European innovation, CES Unveiled Paris was the largest event since its inaugural debut in 2013. The event hosted 1,051 attendees from 44 countries and regions, and featured more than 76 exhibitors.
Now a full-day event, and in collaboration with the Connecting Leaders Club, CES Unveiled Paris debuted the Executive Forum on Innovation, with programming focused on emerging trends including mobility, energy and environment and artificial intelligence. More than 20 speakers were featured, including executives from Axa, Accenture, Google, Salesforce and Valeo, as they discussed the future of innovation, including trends expected at CES this January.
CES 2019 is the world’s most important and influential event. The 2019 event will showcase life-changing technology across every major industry, featuring 4,500 exhibitors across 2.75M net square feet (260K net square meters) of exhibit space. CES provides access to the very latest transformative tech such as 5G connectivity, artificial intelligence, augmented and virtual reality, smart home, smart cities, sports, machine intelligence and more.
CES is also one of the largest displays of vehicle technology in the world and was recently named as USA Today’s 10 Best Auto Shows. The 2019 show will feature more than 150 vehicle tech companies, including eight automakers, featuring the latest concept cars and connected vehicles.
Areas new to CES 2019 include the Tourism Marketplace, as well as the recently announced Resilience area, focused on technologies that keep the world healthy, safe, warm, fed and secure in the face of adversity.
Registration for CES 2019 is now open. For the latest exhibitor news and show announcements, visit CES.tech .
High-definition video b-roll of CES is available for easy download on CESbroll.com . See exclusive photos from the CES show floor, keynotes, conference sessions, events and award ceremonies in the CES photo gallery .
About CES:
CES® is the world's gathering place for all who thrive on the business of consumer technologies. It has served as the proving ground for innovators and breakthrough technologies for 50 years-the global stage where next-generation innovations are introduced to the marketplace. As the largest hands-on event of its kind, CES features all aspects of the industry. Owned and produced by the Consumer Technology Association (CTA)TM , it attracts the world's business leaders and pioneering thinkers. Check out CES video highlights . Follow CES online at CES.tech and on social .
About Consumer Technology Association:
Consumer Technology Association (CTA)™ is the trade association representing the $377 billion U.S. consumer technology industry, which supports more than 15 million U.S. jobs. More than 2,200 companies – 80 percent are small businesses and startups; others are among the world’s best-known brands – enjoy the benefits of CTA membership including policy advocacy, market research, technical education, industry promotion, standards development and the fostering of business and strategic relationships. CTA also owns and produces CES® – the world’s gathering place for all who thrive on the business of consumer technologies. Profits from CES are reinvested into CTA’s industry services.
UPCOMING EVENTS
-
Innovate
Celebrate
- Register
October 15-17, Boston, MA -
CES
Unveiled New York
November 8, New York, NY -
CES
Unveiled Las Vegas
January 6, Las Vegas, NV -
CES
2019
- Register
January 8-11, Las Vegas, NV -
CES
Asia 2019
June 11-13, Shanghai, China
View source version on businesswire.com: https://www.businesswire.com/news/home/20181003005856/en/
Contact:
Consumer Technology Association Teresa Hsu, 703-907-5259 thsu@CTA.tech www.CES.tech or Justin Siraj, 703-907-7415 jsiraj@CTA.tech www.CES.tech
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
